Wedbush Has Bearish Estimate for BCRX FY2025 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Analysts at Wedbush decreased their FY2025 earnings per share (EPS) estimates for BioCryst Pharmaceuticals in a research report issued on Wednesday, April 16th. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings per share of $0.03 for the year, down from their prior estimate of $0.04. Wedbush currently has a “Outperform” rating and a $15.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ Q4 2025 earnings at $0.10 EPS, Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.14 EPS, FY2026 earnings at $0.32 EPS, FY2027 earnings at $0.66 EPS and FY2028 earnings at $0.84 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. During the same period in the prior year, the company earned $0.28 earnings per share. The business’s quarterly revenue was up 40.8% on a year-over-year basis.

Several other equities research analysts have also recently issued reports on BCRX. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $11.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, April 11th. JMP Securities reissued a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Evercore ISI upped their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $15.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Thursday, April 10th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Stock Up 2.5 %

Shares of BioCryst Pharmaceuticals stock opened at $7.40 on Thursday. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -12.13 and a beta of 1.75. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $9.50. The company has a 50-day simple moving average of $7.85 and a two-hundred day simple moving average of $7.73.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $33,000. GAMMA Investing LLC raised its position in BioCryst Pharmaceuticals by 1,161.8% in the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 5,449 shares during the last quarter. Venturi Wealth Management LLC bought a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $46,000. R Squared Ltd acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter valued at about $48,000. Finally, KBC Group NV grew its holdings in shares of BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 4,537 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.